½ÃÀ庸°í¼­
»óǰÄÚµå
1599726

Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå : Á¦Ç°, ¿¬·ÉÃþ, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Blood Glucose Testing Market by Product (Glucose Meter, Insulin Pens, Insulin Pumps & Reservoirs), Age Group (Adults, Geriatrics, Pediatrics), Application, End-User, Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 188 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 193¾ï 7,000¸¸ ´Þ·¯·Î, 2024³â¿¡´Â 212¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.76%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 372¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Ç÷´ç ÃøÁ¤ ½ÃÀåÀÇ ¹üÀ§´Â ´ç´¢º´ °ü¸®¿¡ ÇʼöÀûÀÎ Ç÷´ç ³óµµ¸¦ ÃøÁ¤ÇÏ´Â ±â±â ¹× ±â¼úÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀûÀýÇÑ Ç÷´ç ¼öÄ¡¸¦ À¯ÁöÇϸé ÇÕº´ÁõÀ» ¿¹¹æÇÒ ¼ö ÀÖÀ¸¹Ç·Î Ç÷´ç ¸ð´ÏÅ͸µÀº ´ç´¢º´À» È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ ¿ëµµ´Â ¸¸¼ºÁúȯ °ü¸®, ÀçÅÃÄ¡·á, º´¿ø±îÁö È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ë ¹üÀ§´Â Áø´Ü¼¾ÅÍ, ÀÇ·á ±â°ü, Áý¿¡¼­ ÀÚ°¡ ÃøÁ¤ÇÏ´Â °³ÀΠȯÀÚ µî ´Ù¾çÇÑ ºÐ¾ß¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÁÖ¿ä ¿µÇâ·Â ÀÖ´Â ¼ºÀå ¿äÀÎÀº ´ç´¢º´ À¯º´·ü Áõ°¡, °Ç°­ ÀÎ½Ä Áõ°¡, ±â¼ú ¹ßÀü, Àúħ½ÀÀû ¶Ç´Â ºñħ½ÀÀû Á¦Ç°À¸·ÎÀÇ ÀüȯÀÔ´Ï´Ù. Áö¼ÓÀû Ç÷´ç ÃøÁ¤±â(CGM)¿Í Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû°ú ÅëÇÕµÈ ½º¸¶Æ® ÀÇ·á±â±âÀÇ º¸±ÞÀº »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®, ȯÀÚ °á°ú °³¼±, ¿ø°ÝÀÇ·á ¼Ö·ç¼Ç°ú °°Àº »õ·Î¿î ºñÁî´Ï½º Á¦¾È, eHealth ¹× ¸ÂÃãÇü ȯÀÚ °ü¸® Àü·«ÀÇ È®´ë´Â °æÀï·ÂÀ» È®º¸ÇϰíÀÚ ÇÏ´Â ½ÃÀå ¸®´õµé¿¡°Ô À¯¸ÁÇÑ ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ÷´Ü ±â±âÀÇ ³ôÀº ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ »óȲ, µ¥ÀÌÅÍ ¸ð´ÏÅ͸µ°ú °ü·ÃµÈ ÇÁ¶óÀ̹ö½Ã ¹®Á¦ µîÀÇ Á¦¾à°ú ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â¼ú Á¾¼Ó¼ºÀ¸·Î ÀÎÇØ ƯÈ÷ ÀúÀÚ¿ø ȯ°æ¿¡¼­ÀÇ µµÀÔ °ÝÂ÷°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å°ú ¿¬±¸ ±âȸ¿¡´Â Á¤È®µµ¿Í »ç¿ë ÆíÀǼºÀ» °³¼±ÇÑ ºñ¿ë È¿À²ÀûÀÎ ¸ðµ¨ °³¹ß, ƯÈ÷ Àúħ½ÀÀû ¼Ö·ç¼ÇÀ» ¸ñÇ¥·Î ÇÏ´Â ¸ðµ¨ °³¹ßÀÌ Æ÷ÇԵ˴ϴÙ. Æ÷µµ´ç ¸ð´ÏÅ͸µ°ú ´Ù¸¥ °Ç°­ ÁöÇ¥¸¦ °áÇÕÇÑ ÅëÇÕ À£´Ï½º Ç÷§Æû¿¡ ´ëÇÑ Ãß°¡ ¿¬±¸´Â À¯ÀÍÇÑ Çõ½Å ºÐ¾ßÀÔ´Ï´Ù. ¼¼°è °øµ¿¿¬±¸´Â ¿¬±¸ ³ë·ÂÀÇ ½Ã³ÊÁö¸¦ âÃâÇϰí Á¦Ç° ±â´ÉÀ» °­È­ÇÏ¸ç ½ÃÀå ¹üÀ§¸¦ È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇÐÀº ¿ªµ¿ÀûÀÌ°í °æÀïÀÌ Ä¡¿­Çϸç, ºü¸¥ ±â¼ú Çõ½Å°ú ¼ÒºñÀÚÀÇ ³ôÀº ±â´ëÄ¡¸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. ±â¾÷Àº ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¿Í ¼ºÀåÀ» °­È­Çϱâ À§ÇØ ¼ÒºñÀÚ ±³À° ¹× °¡°Ý Àü·«¿¡ ´ëÇÑ ÅõÀÚ¿Í ÇÔ²² µ¥ÀÌÅÍ º¸¾È ¹× ±ÔÁ¦ Áؼö °­È­¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 193¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 212¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 372¾ï ´Þ·¯
CAGR(%) 9.76%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Ç÷´ç ÃøÁ¤ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Ç÷´ç ÃøÁ¤ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ´ç´¢º´ ¹ßº´·ü Áõ°¡¿Í È¿°úÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ Çʿ伺 ´ëµÎ
    • ÀçÅÃÄ¡·á¿¡¼­ ºñħ½ÀÀû Ç÷´ç ÃøÁ¤ ±â±â äÅà Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ç÷´ç ÃøÁ¤ ÀåºñÀÇ ³ôÀº ºñ¿ë°ú Á¦ÇÑµÈ Á¤È®µµ
  • ½ÃÀå ±âȸ
    • Ç÷´ç ÃøÁ¤¿¡ ´ëÇÑ Á¤ºÎÀÇ ¿ìÈ£ÀûÀÎ ³ë·Â°ú »óȯ Á¤Ã¥
    • Ç÷´ç ¸ð´ÏÅ͸µ ÀåºñÀÇ Áö¼ÓÀûÀÎ ¹ßÀü°ú °³¼±
  • ½ÃÀå °úÁ¦
    • ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç ¹× Á¦Ç° ȸ¼ö »ç·Ê

Portre's Five Forces: Ç÷´ç ÃøÁ¤ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Ç÷´ç ÃøÁ¤ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Ç÷´ç ÃøÁ¤ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Ç÷´ç ÃøÁ¤ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Ç÷´ç ÃøÁ¤ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÏ¿© º¥´õ°¡ Ä¡¿­ÇÑ °æÀï¿¡¼­ ÀÚ½ÅÀÇ À§Ä¡¸¦ °­È­Çϱâ À§ÇÑ Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Ç÷´ç ÃøÁ¤ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Ç÷´ç ÃøÁ¤ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Ç÷´ç ÃøÁ¤ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ Ç÷´ç ÃøÁ¤ ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ ±×¸³´Ï´Ù.

Ç÷´ç ÃøÁ¤ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå : Á¦Ç°º°

  • ±Û·çÄÚ¿À½º ¹ÌÅÍ
    • ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ
    • Ç÷¡½Ã Ç÷´ç ¸ð´ÏÅ͸µ
  • Àν¶¸° Ææ
  • Àν¶¸° ÆßÇÁ¿Í ¸®Àú¹ö
  • ·£½Ë
  • Å×½ºÆ® ½ºÆ®¸³

Á¦7Àå Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå : ¿¬·ÉÃþº°

  • ¼ºÀÎ
  • ³ë³âÀÇÇÐ
  • ¼Ò¾Æ°ú

Á¦8Àå Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå : ¿ëµµº°

  • ÀӽŠ´ç´¢º´
  • 1Çü ´ç´¢º´
  • 2Çü ´ç´¢º´

Á¦9Àå Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ȨÄɾî
  • º´¿ø¡¤Å¬¸®´Ð

Á¦10Àå Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå : À¯Åë ä³Îº°

  • ¿ÀÇÁ¶óÀÎ
  • ¿Â¶óÀÎ

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç÷´çÄ¡ ÃøÁ¤ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • 77 Elektronika Kft.
  • Abbott Laboratories
  • ACON Laboratories, Inc
  • AgaMatrix, Inc.
  • ARKRAY, Inc.
  • Ascensia Diabetes Care Holdings AG
  • B. Braun Medical Ltd.
  • Becton Dickinson and Company
  • Beurer Belgium
  • Dexcom, Inc.
  • ForaCare Suisse AG
  • i-SENS, Inc.
  • Johnson & Johnson
  • LifeScan IP Holdings, LLC
  • Medisana AG
  • Medtronic PLC
  • Merck KGaA
  • Microlife AG
  • Neogen Corporation
  • Nipro Corporation
  • Nova Biomedical
  • Omron Healthcare, Inc.
  • Roche Diagnostics Nederland BV
  • Rossmax International Ltd.
  • Sanofi S.A.
  • Sinocare Inc.
  • Terumo Corporation
  • Trividia Health, Inc.
  • VivaChek Laboratories Inc.
KSA 24.12.03

The Blood Glucose Testing Market was valued at USD 19.37 billion in 2023, expected to reach USD 21.21 billion in 2024, and is projected to grow at a CAGR of 9.76%, to USD 37.20 billion by 2030.

The scope of the blood glucose testing market involves devices and technologies that measure glucose levels in the blood, crucial for diabetes management. Blood glucose monitoring is necessary to manage diabetes effectively, as maintaining the appropriate blood glucose levels prevents complications. This application extends to chronic disease management, home healthcare, and hospitals. The end-use scope includes diverse sectors such as diagnostic centers, healthcare institutions, and individual patients self-monitoring at home. Key influencing growth factors are the increasing prevalence of diabetes, rising health awareness, advancements in technology, and the shift towards minimally invasive or non-invasive products. The widespread adoption of continuous glucose monitors (CGMs) and smart medical devices integrated with cloud-based platforms offers fresh opportunities. These allow real-time data analytics, improving patient outcomes and offering novel business proposals, such as telehealth solutions. The expansion of e-health and tailored patient-care strategies is promising for market leaders aiming to gain a competitive edge. However, the market faces limitations and challenges, such as the high costs of advanced devices, stringent regulatory landscapes, and privacy concerns associated with data monitoring. Moreover, technological dependency may result in disparities in adoption, particularly in low-resource settings. Opportunities for innovation and research include developing cost-effective models with enhanced accuracy and ease of use, especially targeting minimally invasive solutions. Further research into integrated wellness platforms that combine glucose monitoring with other health metrics is a lucrative innovation area. Global collaborations can lead to synergized research efforts, enriching product features and expanding market reach. The nature of the blood glucose testing market is dynamic and competitive, characterized by rapid technological changes and high consumer expectations. Firms should focus on enhancing data security and regulatory compliance, alongside investing in consumer education and affordable pricing strategies, to bolster market presence and growth.

KEY MARKET STATISTICS
Base Year [2023] USD 19.37 billion
Estimated Year [2024] USD 21.21 billion
Forecast Year [2030] USD 37.20 billion
CAGR (%) 9.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Glucose Testing Market

The Blood Glucose Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Global rise in diabetes incidence and the need for effective glucose monitoring solutions
    • Rising adoption of non-invasive blood glucose testing devices in home healthcare settings
  • Market Restraints
    • High costs and limited accuracy of blood glucose testing devices
  • Market Opportunities
    • Favorable government initiatives and reimbursement policies for blood glucose testing
    • Ongoing advancements and improvements in blood glucose monitoring devices
  • Market Challenges
    • Strict regulatory requirements and cases of product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Blood Glucose Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Glucose Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Glucose Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Glucose Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Glucose Testing Market

A detailed market share analysis in the Blood Glucose Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Glucose Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Glucose Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Glucose Testing Market

A strategic analysis of the Blood Glucose Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Glucose Testing Market, highlighting leading vendors and their innovative profiles. These include 77 Elektronika Kft., Abbott Laboratories, ACON Laboratories, Inc, AgaMatrix, Inc., ARKRAY, Inc., Ascensia Diabetes Care Holdings AG, B. Braun Medical Ltd., Becton Dickinson and Company, Beurer Belgium, Dexcom, Inc., ForaCare Suisse AG, i-SENS, Inc., Johnson & Johnson, LifeScan IP Holdings, LLC, Medisana AG, Medtronic PLC, Merck KGaA, Microlife AG, Neogen Corporation, Nipro Corporation, Nova Biomedical, Omron Healthcare, Inc., Roche Diagnostics Nederland BV, Rossmax International Ltd., Sanofi S.A., Sinocare Inc., Terumo Corporation, Trividia Health, Inc., and VivaChek Laboratories Inc..

Market Segmentation & Coverage

This research report categorizes the Blood Glucose Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Glucose Meter, Insulin Pens, Insulin Pumps & Reservoirs, Lancets, and Test Strips. The Glucose Meter is further studied across Continuous Glucose Monitoring and Flash Glucose Monitoring.
  • Based on Age Group, market is studied across Adults, Geriatrics, and Pediatrics.
  • Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
  • Based on End-User, market is studied across Home Care and Hospital & Clinics.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Global rise in diabetes incidence and the need for effective glucose monitoring solutions
      • 5.1.1.2. Rising adoption of non-invasive blood glucose testing devices in home healthcare settings
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and limited accuracy of blood glucose testing devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives and reimbursement policies for blood glucose testing
      • 5.1.3.2. Ongoing advancements and improvements in blood glucose monitoring devices
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory requirements and cases of product recalls
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Adoption of CGM systems in blood glucose to avoid serious, short- and long-term diabetes complications
    • 5.2.2. Application: Increasing uses of blood glucose testing in gestational diabetes to mitigate risks associated with several chronic diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Glucose Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Glucose Meter
    • 6.2.1. Continuous Glucose Monitoring
    • 6.2.2. Flash Glucose Monitoring
  • 6.3. Insulin Pens
  • 6.4. Insulin Pumps & Reservoirs
  • 6.5. Lancets
  • 6.6. Test Strips

7. Blood Glucose Testing Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Geriatrics
  • 7.4. Pediatrics

8. Blood Glucose Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Gestational Diabetes
  • 8.3. Type 1 Diabetes
  • 8.4. Type 2 Diabetes

9. Blood Glucose Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Home Care
  • 9.3. Hospital & Clinics

10. Blood Glucose Testing Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
  • 10.3. Online

11. Americas Blood Glucose Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Blood Glucose Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Blood Glucose Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Focus collaborates with GlucoTrack on implantable continuous blood glucose monitor
    • 14.3.2. Beurer India launches blood glucose monitor device in the Indian market
    • 14.3.3. MTD acquires Ypsomed's Pen Needle and BGM Businesses, strengthening Its position in diabetes care
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 77 Elektronika Kft.
  • 2. Abbott Laboratories
  • 3. ACON Laboratories, Inc
  • 4. AgaMatrix, Inc.
  • 5. ARKRAY, Inc.
  • 6. Ascensia Diabetes Care Holdings AG
  • 7. B. Braun Medical Ltd.
  • 8. Becton Dickinson and Company
  • 9. Beurer Belgium
  • 10. Dexcom, Inc.
  • 11. ForaCare Suisse AG
  • 12. i-SENS, Inc.
  • 13. Johnson & Johnson
  • 14. LifeScan IP Holdings, LLC
  • 15. Medisana AG
  • 16. Medtronic PLC
  • 17. Merck KGaA
  • 18. Microlife AG
  • 19. Neogen Corporation
  • 20. Nipro Corporation
  • 21. Nova Biomedical
  • 22. Omron Healthcare, Inc.
  • 23. Roche Diagnostics Nederland BV
  • 24. Rossmax International Ltd.
  • 25. Sanofi S.A.
  • 26. Sinocare Inc.
  • 27. Terumo Corporation
  • 28. Trividia Health, Inc.
  • 29. VivaChek Laboratories Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦